Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.

Abstract

BACKGROUND Colorectal cancer is the fourth most common cancer worldwide and the second leading cause of cancer-related death. FOLFOX is the most common regimen used in the first-line chemotherapy in advanced colorectal cancer, but only half of the patients respond to this regimen and we have almost no clue in predicting resistance in such first-line application. METHODS To explore the potential molecular biomarkers predicting the resistance of FOLFOX regimen as the first-line treatment in advanced colorectal cancer, we screened microRNAs in serum samples from drug-responsive and drug-resistant patients by microarrays. Then differential microRNA expression was further validated in an independent population by reverse transcription and quantitative real- time PCR. RESULTS 62 microRNAs expressing differentially with fold-change >2 were screened out by microarray analysis. Among them, 5 (miR-221, miR-222, miR-122, miR-19a, miR-144) were chosen for further validation in an independent population (N=72). Our results indicated serum miR-19a to be significantly up-regulated in resistance-phase serum (p=0.009). The ROC curve analysis showed that the sensitivity of serum miR-19a to discriminate the resistant patients from the response ones was 66.7%, and the specificity was 63.9% when the AUC was 0.679. We additionally observed serum miR-19a had a complementary value for cancer embryonic antigen (CEA). Stratified analysis further revealed that serum miR-19a predicted both intrinsic and acquired drug resistance. CONCLUSIONS Our findings confirmed aberrant expression of serum miR-19a in FOLFOX chemotherapy resistance patients, suggesting serum miR-19a could be a potential molecular biomarker for predicting and monitoring resistance to first-line FOLFOX chemotherapy regimens in advanced colorectal cancer patients.

010020020142015201620172018
Citations per Year

381 Citations

Semantic Scholar estimates that this publication has 381 citations based on the available data.

See our FAQ for additional information.

Cite this paper

@article{Chen2013SerumMP, title={Serum miR-19a predicts resistance to FOLFOX chemotherapy in advanced colorectal cancer cases.}, author={Qi Chen and Hong-Wei Xia and Xiao-jun Ge and Yu-Chen Zhang and Qiu-lin Tang and Feng Bi}, journal={Asian Pacific journal of cancer prevention : APJCP}, year={2013}, volume={14 12}, pages={7421-6} }